Carlos Pérez Medina holds a Bachelor’s degree in Chemistry (Universidad Autónoma de Madrid, 2003) and a Ph.D. in Organic Chemistry (UNED, 2008). After a postdoctoral stay at University College London, where he worked on the design and development of radiotracers for positron emission tomography (PET) and single-photon emission computed tomography (SPECT), he moved to Mount Sinai in New York within the frame of CNIC’s CardioImage program. In collaboration with Z. Fayad and W. Mulder, from Sinai’s Translational and Molecular Imaging Institute, his research there revolved around nanomedicine and molecular imaging. More specifically, he developed radiolabeling strategies for lipid nanoparticles (liposomes, nanoemulsions, lipoproteins) for their in vivo evaluation in different murine models of atherosclerosis and cancer, and their translation to large animals. At the same time, he implemented non-invasive imaging methods to monitor nanotherapy and identify possible treatment responders. In addition, he continued his work on radiotracer design and development, this time for atherosclerosis phenotyping by PET imaging. In late 2018, Carlos joined CNIC as head of the Nanomedicine and Molecular Imaging lab, whose research focuses on the integration of molecular imaging into nanomedicine development, and the implementation of non-invasive methods to study cardiovascular disease.